-+ 0.00%
-+ 0.00%
-+ 0.00%

BioVersys to Present Phase 2 Alpibectir-Ethionamide Data in Tuberculosis Patients

PUBT·11/11/2026 06:01:38
Listen to the news
BioVersys to Present Phase 2 Alpibectir-Ethionamide Data in Tuberculosis Patients
  • BioVersys and GSK will present Phase 2 alpibectir-ethionamide data at the Union World Conference on Lung Health, November 17-20, 2026.
  • The Rio de Janeiro conference presentations will cover early antibacterial activity and safety in patients with newly diagnosed drug-sensitive pulmonary tuberculosis.
  • A Phase 2a presentation will detail alpibectir’s enhancement of ethionamide activity against clinical tuberculosis isolates.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioversys AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2432126_en) on November 11, 2026, and is solely responsible for the information contained therein.